PHQ-9 screening in US primary care: flow and follow-up

The U.S. Preventive Services Task Force (USPSTF) recommends screening adults for depression — including pregnant and postpartum persons and older adults — with a Grade B. The Patient Health Questionnaire-9 (PHQ-9) is the instrument most US primary care practices already have in the EHR. The guide problem is not whether to screen; it is building a flow that scores the instrument, routes positive results to diagnostic evaluation, and follows people who never return for the next step. Screening without follow-up is documentation, not care.

What USPSTF actually recommends — and what it does not

The USPSTF final recommendation statement of June 20, 2023 is the clinical north star for US primary care depression screening. For adults 19 and older, including pregnant and postpartum persons and adults 65 and older, who do not already have a diagnosed mental health disorder and are not showing recognized signs or symptoms of depression or suicide risk, the Task Force recommends screening for major depressive disorder (MDD) — Grade B. For screening for suicide risk in that asymptomatic adult population, the Task Force concludes evidence is insufficient — Grade I.

Two sentences in the recommendation do more operational work than the grade letter. First, the pathway to benefit: persons who screen positive must be evaluated further for diagnosis and, if appropriate, provided or referred for evidence-based care. Second, on frequency: the USPSTF found no evidence on optimal screening intervals; a pragmatic approach is to screen adults who have not been screened previously and use clinical judgment — considering risk factors, comorbid conditions, and life events — for additional screening, with ongoing assessment during pregnancy and postpartum as a reasonable approach.

The importance section grounds why practices invest: in 2019, 7.8% (19.4 million) of US adults experienced at least one major depressive episode, and 5.3% (13.1 million) experienced an episode with severe impairment, per the sources the USPSTF cites. Suicide was described as the 10th-leading cause of death in US adults in the recommendation’s importance discussion (2019 data). Those are population figures — your practice’s job is the pathway, not the prevalence headline.

Treatment context in the clinician summary includes psychotherapy, pharmacotherapy, and collaborative care models that use care managers to link primary care clinicians, patients, and mental health specialists. Screening that cannot connect to any of those paths fails the Task Force’s own benefit logic.

What the PHQ-9 is measuring in the exam room

The PHQ-9 is a brief, self-report depression severity instrument validated for primary care. CDC’s NHANES Mental Health — Depression Screener documentation (DPQ_L) describes how the federal survey administers it: nine symptom questions about the past two weeks, each scored 0 to 3 for “not at all,” “several days,” “more than half the days,” and “nearly every day,” producing a total from 0 to 27 when responses are complete. An additional functional impairment question is asked if any symptom is endorsed. The documentation cites Kroenke and colleagues’ validation work (PubMed record for the 2001 JGIM paper) for pre-defined cut-points used to assess major depression and severity.

Operationally, primary care teams should treat the PHQ-9 as a screen and severity tracker, not as a stand-alone diagnosis. A positive or elevated score triggers diagnostic evaluation — clinical interview, differential diagnosis, safety assessment — by a qualified clinician. Item 9 (thoughts of being better off dead or of self-harm) requires an immediate safety pathway, not a “follow up next visit” sticky note. Practices that auto-score the PHQ-9 in the EHR without routing item-9 positives to same-day clinical review have built a liability machine, not a screening program.

A primary care screening flow that survives Monday

A flow that only works when the clinic is quiet does not work. Build for the overloaded Tuesday.

1. 1
   Offer the instrument before the clinician enters

   Tablet, paper, or portal completion in the past two weeks — same nine items, scored consistently.

2. 2
   Auto-score and flag item 9

   Any nonzero item-9 response routes to same-day clinical safety review before the patient leaves.

3. 3
   Clinician reviews score in context

   Positive or elevated scores trigger diagnostic evaluation — not automatic medication.

4. 4
   Document the plan and the owner

   Treat in clinic, refer, collaborative care — with a named next appointment or outreach date.

5. 5
   Close the loop after the visit

   Track whether the diagnostic visit, therapy start, or psychiatry referral actually occurred.

Staff roles should be explicit. Medical assistants can administer and score. Clinicians own diagnosis and treatment decisions. Care managers or referral coordinators own the loop after a positive screen. Reception owns outreach when a scheduled follow-up is missed. If every role “kind of” owns follow-up, nobody does.

Follow-up is where the Grade B is won or lost

USPSTF’s pathway language is the audit standard: screen → further evaluation → evidence-based care when appropriate. Practices should measure three conversion rates, not just screening completion percentage:

1. Screened among eligible visits — are you offering the instrument?
2. Evaluated among positive screens — did diagnostic evaluation happen within a defined window?
3. Engaged among those needing treatment — did therapy, medication management, or collaborative care actually start?

Missed follow-up visits are an access problem as much as a clinical one. Confirmation calls or messages, easy reschedule, and outreach when someone no-shows a behavioral health intake are part of the depression pathway — not a separate “marketing” workstream. The same front-office discipline that protects ordinary appointment access protects screening benefit.

Collaborative care, which the USPSTF clinician summary flags via Community Preventive Services Task Force recommendations, is one evidence-aligned way to keep follow-up inside primary care rather than hoping specialty waitlists clear. Even without a full collaborative care build, a weekly registry review of open positive screens is the minimum viable follow-up structure.

Perinatal depression overlaps this flow — it does not replace it

USPSTF’s Grade B explicitly includes pregnant and postpartum persons. Risk factors listed in the clinician summary for perinatal depression include life stress, low social support, history of depression, partner dissatisfaction, and history of abuse. The recommendation also notes rising self-reported depression during pregnancy in PRAMS data cited there (11.6% in 2016 to 14.8% in 2019).

That does not mean one six-week postpartum PHQ-9 finishes the job. Our related analysis on postpartum depression screening in primary care focuses on the coverage window and visit timing problem: Medicaid’s postpartum coverage expansion does not automatically create a screening calendar. Adult screening workflows and perinatal workflows should share instruments and safety paths, then diverge on cadence and obstetric coordination. Do not build two disconnected PHQ-9 programs that neither talk to the EHR registry nor share escalation rules.

What your practice can do this week

This is a guide, not a product pitch. The work is operational.

For US practice operations more broadly, the market context lives on /en/united-states/. Depression screening earns its Grade B only when the pathway after the score is as reliable as the checkbox that captured it.